




# Análisis de Plataformas de Integración Clínico- Omicas y Métodos Estadísticos Predictivos para Apoyo al Diagnóstico y Tratamiento

Patricio Araneda García  
Magíster (c) en Informática Médica

Prof. Dr. Rodrigo Assar





# Genómica - Proteómica - Transcriptómica

PHR - EMR - HER

i2b2

Métodos - R

i2b2+R

## Temario

Datos Omicos

Datos Clínicos

Integración

Apoyo Estadístico

Plataforma

Referencias

nanoschematic<sup>®</sup>

DNA contains the genetic information that allows all modern living things to function, grow and reproduce. However, it is unclear how long in the 4-billion-year history of life DNA has performed this function, as it has been proposed that the earliest forms of life may have used RNA as their genetic material.<sup>[93][10]</sup> RNA may have acted as the central part of early cell metabolism as it can both transmit genetic information and carry out catalysis as part of ribozymes.<sup>[11]</sup> This ancient RNA world where nucleic acid would have been used for both catalysis and genetics may have influenced the evolution of the current genetic code based on four nucleotide bases. This would occur, since the number of different bases in such an organism is a trade-off between a small number of bases increasing replication accuracy and a large number of bases decreasing the catalytic efficiency of ribozymes.<sup>[12]</sup>

However, there is no direct evidence of ancient genetic systems, as recovery of DNA from most fossils is impossible, because DNA will survive in the environment for less than one million years and quickly degrades into short fragments. In contrast, RNA remains for older DNA. Very little, if any, is known about the evolution of a genetic system from a non-coding one.

# Introducción

La génesis y el desarrollo de enfermedades de alto impacto como el cáncer y otras están relacionado a la disfunción de los genes.

La secuenciación del genoma humano ha impactado la investigación del cáncer a nivel molecular.

## Medicina Traslacional

Facilitar la Transición desde la investigación básica hacia el tratamiento clínico al paciente.

Desarrollo de nuevas drogas y/o procedimientos que basados en data genómica promuevan un tratamiento personalizado.

# Datos Ómicos

## Genómica

Estudio integral e interdisciplinarios del genoma

- Definir función genica basado en su secuencia
- Determinar la interacción entre genes

## Transcriptómica

Estudio y comparación de los conjuntos de ARNm o transcriptomas.

- Análisis de microarrays
- Determinación de expresión genica

## Proteómica


Estudio del conjunto de proteínas, estructura y función expresados a partir de un genoma determinado.

- Identificación de los componentes de proteína.
- Expresión diferencial
- Caracterización de las interacciones

# Datos Clínicos

## Gestión Clínica

- Privacidad
  - Exactitud
  - Completitud
  - Estandarización
- 
- Integración funcional a nivel de servicios
  - Interoperabilidad entre sistemas






Integración

# Plataformas de integración


## Metas

- Almacenar e integrar datos clínicos y ómicos
- Cruce de información
- Marco de análisis (generación de hipótesis médica)



# Desiderata

- Privacidad
- Interoperabilidad
- Granularidad
- Mantenimiento
- Personalización
- Análisis Predictivo



# Plataformas de integración [8]

- **i2b2** (Informatics for Integrating Biology & the Bedside).
- **ICOD** (Integrated Clinical Omics Database).
- **IDASH** (Integrating data for analysis, anonymization and sharing).
- **BRISK** (Biology-Related Information Storage Kit).

## Características

Soporte de interoperabilidad limitada o nula.

Uso de estándares limitado.


Integración con herramientas estadísticas de terceros (R).

En almacén local o cloud.


Privacidad de datos (anonimicidad)

# i2b2 [14]


- Plataforma Opensource
- National Center for Biomedical Computing (NCBC)
- Cores
  - Harvard Hospitals
  - MIT
  - Harvard School of Public Health
  - Harvard Medical School
  - Harvard/MIT Division of Health Sciences and Technology




# i2b2 - Core



# i2b2 - Core



# i2b2 - Personalización




# i2b2 | Query

The image shows the i2b2 Query tool interface. On the left side, there are three panes: "Navigate Terms" (listing categories like 1000 Genomes Demographics, Clinical Trials, Custom Metadata, Demographics, Diagnoses, Circulatory system, Conditions in the perinatal period, Congenital anomalies, and Digestive system), "Workplace" (listing a "demo" folder containing Acute Rheumatic@09:55:26 [12-1-2014] [demo], AAA [12-3-2014] [demo], BY\_PATIENTSET@15:13:25 [9-15-2014] [demo], Cardiac Related Queries, Ischemic heart @10:21:45 [12-3-2014] [demo], Patients with Ischemic Heart facts, and Endocrine disorders), and "Previous Queries" (listing Population@21:58:03 [12-12-2014] [demo], Population@21:56:06 [12-12-2014] [demo], Female@21:53:43 [12-12-2014] [demo], Female@21:53:29 [12-12-2014] [demo], CEU:N/W-Hyperte@21:00:12 [12-12-2014] [demo], and CEU:N/W-Hyperte@20:58:38 [12-12-2014] [demo]). A large white arrow points from the Workplace pane towards the "Query Tool" pane on the right. The "Query Tool" pane contains fields for "Query Name:" and "Temporal Constraint:" (set to "Treat all groups independently"). It features a grid for defining query groups: "Group 1" (with "Occurrences > 0x" and "Exclude" options), "Group 2" (with "Occurrences > 0x" and "Exclude" options), and "Group 3" (with "Occurrences > 0x" and "Exclude" options). Below the grid, there are instructions: "one or more of these" pointing to the first group, "AND" between groups, and "drop a term on here" pointing to the third group. At the bottom of the "Query Tool" pane are buttons for "Run Query", "Clear", and "Print Query", along with navigation buttons for "1 Group", "New Group", and "Run All".


# Análisis Predictivo | R [12]

Integración de información para estudios estadísticos analíticos y predictivos.


Estudio de grandes volúmenes de datos.




# Plataformas de integración



# Plataformas de integración



# ETL (Extract, Transformation and Load)



- Basado en el modelo de datos de i2b2 (Hechos=medidas, dimensiones=conceptos o descripciones)
- Arquitectura escalable, el contenido es mapeado a los conceptos en repositorio de metadatos
- Rápido, incremental, con un proceso de desarrollo aditivo


# Perspectivas



# i2b2 y Big Data


# Integración de datos no relacionales y no estructurados.

- Sistemas de monitoreo de paciente.
  - Experimentos Next Generation Sequencing.




# SHRINE (Shared Health Research Information Network)


- Basada en plataforma i2b2.
- Desarrollada por Harverd Catalyst: the Harvard Clinical and Translational Science Center
- Compila grandes grupos de pacientes bien caracterizados.
- Determina la cantidad de pacientes de cada hospital participante definidos en base a criterios de inclusión/exclusión.
- La información es agregada, protege la privacidad del paciente.
- Genera investigaciones a nivel regional o nacional.




## 1. Pathology Unit




## 2. Biobank "Bruno Boerci"




## 4. i2b2



## 3. FSM HIS



**i2b2**  
Informatics for Integrating Biology & the Bedside





## Personalización

- 7 web plugins.
- 1 Módulo de integración con R.
- 1 Módulo de procesamiento de lenguaje natural.
- Múltiples tareas ETL.

Oncología (2010): 28.838  
Cardiología (2009): 6.334

# ETL: Talend Open Studio

- Herramientas de análisis.
- Integración de operaciones / procesos.
- Sincronización o replicación de bases de datos.
- Transformaciones de datos complejos y carga.
- Calidad de datos.



# Conclusiones

- La interrelación de datos clínicos requiere estandarización de la información.
- Procesos de ETL (extracción, transformación y carga) es determinante en la obtención de datos relevante.
- i2B2 se presenta como la opción mas ampliamente aceptada.
- i2B2 Requiere desarrollo de modelos específicos a la necesidad.
- El gran volumen de datos requiere adopción de plataformas de Big Data para almacenamiento y análisis.



# Referencias

- [1] L. J. Frey, L. Lenert, and G. Lopez-Campos, "EHR Big Data Deep Phenotyping. Contribution of the IMIA Genomic Medicine Working Group.," *Yearb. Med. Inform.*, vol. 9, no. 1, pp. 206–11, Jan. 2014.
- [2] S. Jauhari and S. Rizvi, "Mining Gene Expression Data Focusing Cancer Therapeutics: A Digest," *IEEE/ACM Trans. Comput. Biol. Bioinforma.*, vol. 11, no. 3, pp. 533–547, 2014.
- [3] M. Lawrence and M. Morgan, "Scalable Genomics with R and Bioconductor," *Stat. Sci.*, vol. 29, no. 2, pp. 214–226, May 2014.
- [4] M. G. de Lecea and M. Rossbach, "Translational genomics in personalized medicine – scientific challenges en route to clinical practice," *Hugo J.*, vol. 6, no. 1, p. 2, 2012.
- [5] McMurry AJ, Murphy SN, MacFadden D, Weber G, Simons WW, et al. (2013) SHRINE: Enabling Nationally Scalable Multi-Site Disease Studies. *PLoS ONE* 8(3).
- [6] A. R. Post, T. Kurc, S. Cholleti, J. Gao, X. Lin, W. Bornstein, D. Cantrell, D. Levine, S. Hohmann, and J. H. Saltz, "The Analytic Information Warehouse (AIW): a platform for analytics using electronic health record data.," *J. Biomed. Inform.*, vol. 46, no. 3, pp. 410–24, Jun. 2013.
- [7] J. F. Hurdle, S. C. Haroldsen, A. Hammer, C. Spigle, A. M. Fraser, G. P. Mineau, and S. J. Courdy, "Identifying clinical/translational research cohorts: ascertainment via querying an integrated multi-source database.," *J. Am. Med. Inform. Assoc.*, vol. 20, no. 1, pp. 164–71, Jan. 2013.
- [8] V. Canuel, B. Rance, P. Avillach, P. Degoulet, and A. Burgun, "Translational research platforms integrating clinical and omics data: a review of publicly available solutions.," *Brief. Bioinform.*, Mar. 2014.
- [9] R. Sabatier, A. Gonçalves, and F. Bertucci, "Personalized medicine: present and future of breast cancer management.," *Crit. Rev. Oncol. Hematol.*, vol. 91, no. 3, pp. 223–33, Sep. 2014.
- [10] R. L. Schilsky, "the future is now," vol. 9, no. May, pp. 363–366, 2010.
- [11] D. Segagni, V. Tibollo, A. Dagliati, A. Zambelli, S. G. Priori, and R. Bellazzi, "An ICT infrastructure to integrate clinical and molecular data in oncology research.," *BMC Bioinformatics*, vol. 13 Suppl 4, no. Suppl 4, p. S5, Jan. 2012.
- [12] D. Segagni, F. Ferrazzi, C. Larizza, V. Tibollo, C. Napolitano, S. G. Priori, and R. Bellazzi, "R engine cell: integrating R into the i2b2 software infrastructure.," *J. Am. Med. Inform. Assoc.*, vol. 18, no. 3, pp. 314–7, May 2011.
- [13] E. Zapletal, N. Rodon, N. Grabar, and P. Degoulet, "Methodology of integration of a clinical data warehouse with a clinical information system : the HEGP case," in *MEDINFO 2010*, 2010, pp. 193–197.
- [14] M. D. Natter, J. Quan, D. M. Ortiz, A. Bousvaros, N. T. Ilowite, C. J. Inman, K. Marsolo, A. J. McMurry, C. I. Sandborg, L. E. Schanberg, C. a Wallace, R. W. Warren, G. M. Weber, and K. D. Mandl, "An i2b2-based, generalizable, open source, self-scaling chronic disease registry.," *J. Am. Med. Inform. Assoc.*, vol. 20, no. 1, pp. 172–9, Jan. 2013.
- [15] B. Knoppers, "Framework for responsible sharing of genomic and health-related data," *Hugo J.*, vol. 8, no. 1, p. 3, 2014.
- [16] S. Jakka and M. Rossbach, "An economic perspective on personalized medicine," *Hugo J.*, vol. 7, no. 1, p. 1, 2013.
- [17] R. L. Richesson, M. M. Horvath, and S. a Rusincovitch, "Clinical research informatics and electronic health record data.," *Yearb. Med. Inform.*, vol. 9, no. 1, pp. 215–23, Jan. 2014.



# Análisis de Plataformas de Integración Clínico- Omicas y Métodos Estadísticos Predictivos para Apoyo al Diagnóstico y Tratamiento

Patricio Araneda García  
Magíster (c) en Informática Médica

Prof. Rodrigo Assar

